Johnson & Johnson Earns Attractive Rating Following COVID Vaccine News

Johnson & Johnson has held up surprisingly well considering the flood of negative headlines in recent years. As it's expected to be a frontrunner in the race to develop the first successful COVID-19 vaccine, we were curious about whether it is considered a "buy." This is what our AI found.
Read The Rest at :